WDC
41
-2
HPE
55
11
VRSN
53
3
V
60
-6
WMT
74
2
SYK
64
-4
A
36
2
VRSK
73
5
DHI
48
3
PDCO
35
-3
EQR
54
-2
AKAM
43
3
SO
55
-2
M
20
-4
DVN
16
3
BEN
45
3
JWN
40
-2
EW
37
-2
NOV
58
3
VRTX
46
2
WDC
41
-2
HPE
55
11
VRSN
53
3
V
60
-6
WMT
74
2
SYK
64
-4
A
36
2
VRSK
73
5
DHI
48
3
PDCO
35
-3
EQR
54
-2
AKAM
43
3
SO
55
-2
M
20
-4
DVN
16
3
BEN
45
3
JWN
40
-2
EW
37
-2
NOV
58
3
VRTX
46
2
Financhill
Back

Stereotaxis 10K Form

Sell
38

STXS
Stereotaxis

Last Price:
2.05
Seasonality Move:
14.66%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive STXS News And Ratings

See the #1 stock for the next 7 days that we like better than STXS

STXS Financial Statistics

Sales & Book Value

Annual Sales: $26.77M
Cash Flow: $-4.34M
Price / Cash Flow: 0
Annual Sales: $0.13
Price / Book: 15.67

Profitability

EPS (TTM): -0.27000
Net Income (TTM): $-21.57M
Gross Margin: $14.86M
Return on Equity: -108.68%
Return on Assets: -50.67%

Stereotaxis Earnings Forecast

Key Stereotaxis Financial Ratios

  • The Gross Profit Margin over the past 24 years for STXS is 55.51%.
  • The Selling, General & Administrative Expenses for STXS have been equal to 98.71% of Gross Profit Margin.
  • The Research & Development expenses have been 38.37% of Revenue.
  • The Interest Expense is 16.67% of Operating Income.
  • The Net Earning history of STXS is -77.37% of Total Revenues.
  • Per Share Earnings over the last 24 years have been positive in 13 years.

Stereotaxis Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: STXS
CUSIP: 85916J
Website: stereotaxis.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.39
Quick Ratio: 0.9

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

STXS Technical Analysis vs Fundamental Analysis

Sell
38
Stereotaxis (STXS) is a Sell

Is Stereotaxis a Buy or a Sell?

  • Stereotaxis stock is rated a Sell
    The current Stereotaxis [STXS] share price is $2.03. The Score for STXS is 38, which is 24% below its historic median score of 50, and infers higher risk than normal.